PEC Chat専用掲示板

[記事表示に戻る] [ツリートップの表示に戻る] 
-『dDefiLgrilihpoGwWnE』Herbert(1/3-18:14)No.14463
トップに戻る
14463dDefiLgrilihpoGwWnEHerbert E-mail URL1/3-18:14
記事番号10655へのコメント
How do you know each other? http://www.karenstoys.com/sites/default/files/pharmacy/index.php/super-p-force-sverige-7341.pdf super p force side effects The FDA is clearly impressed with volasertib data to date. A Phase II study in patients with previously untreated AML ineligible for intensive therapy compared volasertib in combination with the established therapy of low-dose cytarabine (LDAC) versus LDAC alone. Objective responses were observed in 31% of patients (13 of 42) treated with the combo compared to 13.3% (6 of 45) treated with LDAC alone.